Your shopping cart is currently empty

S130 is a high affinity, selectiveATG4B (a major cysteine protease) inhibitor (IC50 of 3.24 μM).It suppresses autophagy flux.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $297 | 6-8 weeks | 6-8 weeks | |
| 25 mg | $987 | 6-8 weeks | 6-8 weeks | |
| 50 mg | $1,360 | 6-8 weeks | 6-8 weeks | |
| 100 mg | $1,860 | 6-8 weeks | 6-8 weeks | |
| 1 mL x 10 mM (in DMSO) | $318 | 6-8 weeks | 6-8 weeks |
| Description | S130 is a high affinity, selectiveATG4B (a major cysteine protease) inhibitor (IC50 of 3.24 μM).It suppresses autophagy flux. |
| Targets&IC50 | ATG4B:3.24 µM |
| In vitro | S130 suppresses autophagy and activates apoptosis by inhibiting ATG4B, leading to enhanced cytotoxicity. S130 (0-25 μM; 48 hours) induces cell death through ATG4B inhibition at doses higher than 6.3 μM, without causing necroptosis. Nutrient deprivation enhances S130-induced cytotoxicity. S130 (0-10 μM; 24 hours) suppresses approximately 79% of full-length LC3-GST cleavage at 10 μM, while no substrates were processed in ATG4B KO cells. S130 exhibits significant inhibitory effects on ATG4B. |
| In vivo | Tumor growth suppressed by S130 (20 mg/kg; i.p.; daily; 3 weeks), S130 shows an efficient in vivo antitumor effect with a sound safety on vital organs. |
| Molecular Weight | 387.47 |
| Formula | C24H25N3O2 |
| Cas No. | 1160852-22-1 |
| Smiles | CCN(CC)CCCNC(=O)c1cnc2C(=O)c3ccccc3-c3cccc1c23 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 125 mg/mL (322.61 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (8.52 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.